How to Include Genetic Analysis in Clinical Trials

The demand for genetic analysis in clinical trials is increasing. This is partly due to the growing realisation that understanding the genetic variation within a clinical trial population can improve the design, safety and outcome of the trial. A second major driver is the encouragement that the regulatory authorities, in particular the FDA, are giving to the inclusion of a pharmacogenomic element. For the pharmaceutical company or CRO wishing to incorporate a genetic analysis component there are now a number of service providers who have both the technical ability and appropriate quality systems to provide clinical trial grade genotyping.

Dr Stephen Little is Chief Executive and Co-Founder of DxS Ltd, a UK biotech company providing pharmacogenomic services to the health care industry. Prior to forming DxS, he was a Board and Executive Team Member at AstraZeneca Diagnostics with overall responsibility for R&D within the business.

Dr Little has extensive experience in the development of nucleic acid-based diagnostic technology, products and services for human genetic analysis gained from over 20 years working in the biotechnology industry.

Düsseldorf, March 24, 2020. We as Gerresheimer face up to the special situation in view of the corona virus which is spreading worldwide. We are aware of our role as a key supplier of medicines and supplies for everyday life.More info >>

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.More info >>